Mouse IGF-1(Insulin-like Growth Factor 1) ELISA Kit
中文名称:小鼠胰岛素样生长因子1(IGF-1)酶联免疫吸附测定试剂盒

Price:
- 反应性: Mouse
- 检测范围: 15.63-1000 ng/mL
- 灵敏度: 9.38 ng/mL
产品应用 | ELISA |
检测原理 | 本试剂盒采用双抗体夹心ELISA法。用抗小鼠IGF-1抗体包被于酶标板上,实验时样品(或标准品)中的小鼠IGF-1会与包被抗体结合。后依次加入生物素化的抗小鼠IGF-1抗体和辣根过氧化物酶标记的亲和素,抗小鼠IGF-1抗体与结合在包被抗体上的小鼠IGF-1结合,生物素与亲和素特异性结合而形成免疫复合物,游离的成分被洗去。加入显色底物(TMB),TMB在辣根过氧化物酶的催化下呈现蓝色,加终止液后变成黄色。用酶标仪在450 nm波长处测OD值,IGF-1浓度与OD450值之间呈正比,通过绘制标准曲线计算出样品中IGF-1的浓度。 |
反应类型 | Sandwich-ELISA |
规格 |
96 T
/ 48 T
/ 96 T × 5
|
反应时间 | 3 h 30 min |
反应性 | Mouse |
检测方法 | 比色法;ELISA;夹心法 |
检测范围 | 15.63-1000 ng/mL |
灵敏度 | 9.38 ng/mL |
样本体积 | 100 μL |
样本类型 | 血清、血浆或其他生物体液 |
特异性 | 可检测样本中的小鼠IGF-1,且与其它类似物无明显交叉反应 |
精密度 | 板内,板间变异系数均<10% |
回收率 | 80%-120% |
储存条件 | 2-8℃ |
有效期 | 12个月 |
数据处理 |
-
Fasting-mimicking diet potentiates anti-tumor effects of CDK4/6 inhibitors against breast cancer by suppressing NRAS- and IGF1-mediated mTORC1 signaling
IF: 15.800Journal: DRUG RESISTANCE UPDATES (2024)Reactivity:MouseSample Type:Serum -
CD14loCD301b+ macrophages gathering as a proangiogenic marker in adipose tissues
IF: 5.000 -
Mechanically strained osteocyte-derived exosomes contained miR-3110-5p and miR-3058-3p and promoted osteoblastic differentiation
IF: 2.900 -
Retinol-Binding Protein 4 Accelerates Metastatic Spread and Increases Impairment of Blood Flow in Mouse Mammary Gland Tumors
IF: 6.126 -
Serum Proteins as New Biomarkers for Whole-Body Exposure to High- and Low-LET Ionizing Radiation.
IF: 2.438 -
Antihypernociceptive, Anxiolytic, and Antidepressant Properties of Aqueous and Ethanol Extracts of Dissotis thollonii Cogn. (Melastomataceae) in Mice
Journal: Advances in Pharmacological and Pharmaceutical Sciences (2020)PMID:33015629Reactivity:MouseSample Type:Serum,Tissue homogenate -
The Warburg effect in human pancreatic cancer cells triggers cachexia in athymic mice carrying the cancer cells
IF: 3.288 -
Emodin and rhein decrease levels of hypoxia-inducible factor-1α in human pancreatic cancer cells and attenuate cancer cachexia in athymic mice carrying these cells
IF: 5.168 -
The effect of maternal obesity on the expression and functionality of placental P-glycoprotein: Implications in the individualized transplacental digoxin treatment for fetal heart failure
IF: 2.710